asco@alo33:161798 JSONTXT

Background: We aim to quantify the relationship beteen pretreatment comorbidity and survival outcomes for patients ith locally-advanced larynx cancer. Methods: We retrospectively revieed records of patients treated for T3 and T4 laryngeal squamous cell cancer at MD Anderson Cancer Center beteen 1985 and 2011 after institutional revie board approval. Baseline pretreatment comorbidity data ere collected and age-adjusted Charlson comorbidity index CCI as calculated for each case. Kaplan-Meier and Cox proportional hazards modeling ere used to determine associations ith survival. Results: Among 548 patients ith median age of 59 years range 31-91 , 58 percent ere treated ith larynx preservation and the rest ith total laryngectomy and adjuvant radiotherapy. 19 percent received induction chemotherapy 54 percent platinum + taxane, 40 percent platinum-based . 34 percent received concurrent therapy 84 percent platinum-based . 237 patients 43 percent suffered at least one comorbid condition prior to therapy. Cardiovascular diseases ere the most common comorbidity 43 percent . Recursive partitioning shoed CCI 3 associated ith poorer outcomes p lt 0.001 . For all patients, 5-yr and 10-yr overall survival OS for patients ith CCI x2264; 3 n = 443, 81 percent ere superior to CCI 3 n = 105, 19 percent , Plt 0.0001 , though 5 and 10-yr disease-specific survival DSS ere non-different 70 percent vs. 66 percent at 5-yr and 60 percent vs. 66 percent at 10-yr, P= 0.17 . 5-yr and 10-yr non-cancer cause specific survival NCCSS improved for age adjusted CCI x2264; 3 88 percent vs. 67 percent at 5-yr and 68 percent vs. 28 percent at 10-yr, Plt 0.0001 . Multivariate analysis revealed that age adjusted CCI 3 and nodal staging as independent predictors for orse OS after Bonferroni correction P = 0.0002 and P = 0.0001, respectively . Competing risk analysis shoed risk of non-cancer death exceeded death from disease after 3 years for CCI 3; hile non-cancer risk of demise never exceeded cancer-specific risk during follo up for CCI x2264; 3. Conclusions: The age-adjusted Charlson comorbidity index is a significant predictor of NCCSS and OS for locally-advanced larynx cancer patients, but is not associated ith DSS. After 3 years, patients ith CCI 3 have non-cancer mortality risk greater than that of cancer-related death.,J Clin Oncol 34, 2016 suppl; abstr 6038 00:00.0,Head and Neck Cancer